The AAPS PharmSciTech article Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability, was awarded the 2020 AAPS PharmSciTech High Impact Article Award during PharmSci 360. Corresponding author Peter Mack, Ph.D., accepted the award on behalf of coauthors Amber Doty, Jon Schroeder, Kou Vang, Mark Sommerville, Ph.D., Mervin Taylor, Brad Flynn, and David Lechuga-Ballesteros, Ph.D.
This open access article demonstrates improvements in metered dose inhaler suspension formulations to overcome variability in delivery. “To ensure consistency of clinical outcomes, orally inhaled therapies must exhibit consistent delivered dose and aerosol properties at the time of manufacturing, throughout storage, and during various patient-use conditions,” explain the authors. “Achieving consistency across these scenarios has presented a significant challenge, especially for combination products that contain more than one drug. This study characterized the delivered dose and aerosol properties of glycopyrrolate/formoterol fumarate metered dose inhaler….”
The formulation used an innovative co-suspension delivery technology. The study assessed
delivered-dose uniformity through dose frequency and aerosol properties such as percent fine particle fraction and mass median aerodynamic diameter. The researchers found that this suspension delivery technology was effective in reducing variability, even when applying patient-handling errors such as reduced shake energy and delays between shaking and actuation.
Better formulation methods for metered dose inhalers will lead to more effective treatment for chronic respiratory disease.
Read the full article for FREE to learn more about this study and watch Mack’s award acceptance video!
]